Complete Guide to Amlitelimab Pharmacokinetics
Overview
Amlitelimab is a mAb used in the Immunology therapeutic area. It is indicated for Atopic Dermatitis. Population PK simulator for amlitelimab anti-OX40L antibody. Explore dosing regimens in atopic dermatitis.
Mechanism of Action
Amlitelimab exerts its pharmacological effect by targeting OX40L. As a mAb, it modulates this target to achieve therapeutic efficacy in Atopic Dermatitis. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PopPK models for Amlitelimab:
| Parameter | Value |
|---|---|
| Q | 0.5-0.8 L/day |
| Vc | 3-4 L |
| Vp | 2-3 L |
| dose | 250 mg SC q4w (after loading) |
| ka SC | 0.2-0.3 day⁻¹ |
| IIV CL | 30-40% CV |
| t half | ~20 days |
| target | OX40 ligand |
| CL linear | 0.15-0.25 L/day |
| bioavailability SC | 0.6-0.7 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Amlitelimab is administered via the SC/IV route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Immunology therapeutic area, for the treatment of Atopic Dermatitis, understanding the pharmacokinetics of Amlitelimab is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Amlitelimab pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Amlitelimab PK Simulator
Explore Amlitelimab pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Amlitelimab?
The elimination half-life of Amlitelimab depends on patient-specific factors. Based on published models, the typical half-life is approximately ~20 days.
How is Amlitelimab administered?
Amlitelimab is administered via the SC/IV route. It is indicated for Atopic Dermatitis. As a mAb, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Amlitelimab?
Key pharmacokinetic parameters for Amlitelimab include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Amlitelimab dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Amlitelimab PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.